This review summarizes the rationale, efficacy data, and practical tips for using sacubitril/valsartan in patients with HFrEF.
Sacubitril/valsartan, a first‐in‐class angiotensin receptor–neprilysin inhibitor (ARNI) inhibits angiotensin II and neprilysin, enhancing circulating vasoactive peptides. It is recommended in heart failure with reduced ejection fraction (HFrEF) as a result of the PARADIGM‐HF trial.1 This review discusses the rationale for neprilysin inhibition, data supporting efficacy, and practical tips for patient selection and utilization.
No takes yet. Share an insight, caveat, or question.
Barghash et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: